FAI | Jotup

Web3 Goes Borderless: FuturesAI Launches Next-Gen Derivatives Trading Platform

Retrieved on:

Sunday, April 7, 2024

Revolutionary, Friends, AVAX, Dapp, SOL, KYC, AI, Telegraphy, ETH, Partner, FAI, Cryptocurrency

With its innovative approach to futures trading, FuturesAI eliminates barriers, enabling users to trade freely and profitably without the need for cumbersome KYC procedures.

Key Points:

With its innovative approach to futures trading, FuturesAI eliminates barriers, enabling users to trade freely and profitably without the need for cumbersome KYC procedures.
In addition to its innovative technology, FuturesAI offers a range of trading utilities and features designed to enhance the trading experience.
As for the trading utilities and features, FuturesAI provides:
Telegram Bot: A cutting-edge Telegram bot that offers a seamless user experience, enabling traders from all corners of the world to engage in crypto derivatives trading.
Whether you're a seasoned trader or a newcomer to the world of crypto futures, FuturesAI provides a platform where traders can thrive and succeed.

American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

Retrieved on:

Monday, April 8, 2024

Cardiovascular disease, Chest pain, Psoriasis, Coronary artery disease, Risk, Inflammation, Patient, Cardiovascular Research, Death, Plaque, Artery, American College, CCTA, Apolipoprotein, Heart, ACC, FAI, Pharmaceutical industry

ATLANTA, April 8, 2024 /PRNewswire/ -- Abcentra LLC, a clinical-stage biopharmaceutical company specializing in coronary artery disease, presented the latest results from a Phase 2a pilot, placebo-controlled, randomized clinical trial of Orticumab, a new drug with a novel mechanism of action to combat coronary inflammation, at the American College of Cardiology (ACC) Annual Scientific Sessions in Atlanta. The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.

Key Points:

The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.
Orticumab is a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease.
Abcentra partnered with Caristo Diagnostics to leverage its CaRi-Heart AI technology to measure changes in patients' coronary artery inflammation as result of therapeutic intervention.
The results from this trial indicate that targeting oxLDL with Orticumab may reduce residual inflammatory risk and improve outcomes for patients with cardiovascular disease.

American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

Retrieved on:

Monday, April 8, 2024

ATLANTA, April 8, 2024 /PRNewswire/ -- Abcentra LLC, a clinical-stage biopharmaceutical company specializing in coronary artery disease, presented the latest results from a Phase 2a pilot, placebo-controlled, randomized clinical trial of Orticumab, a new drug with a novel mechanism of action to combat coronary inflammation, at the American College of Cardiology (ACC) Annual Scientific Sessions in Atlanta. The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.

Key Points:

The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.
Orticumab is a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease.
Abcentra partnered with Caristo Diagnostics to leverage its CaRi-Heart AI technology to measure changes in patients' coronary artery inflammation as result of therapeutic intervention.
The results from this trial indicate that targeting oxLDL with Orticumab may reduce residual inflammatory risk and improve outcomes for patients with cardiovascular disease.

Bombardier’s Global 7500 Jet Sets More Than 30 Speed Records, as Precedent-Setting Program Operates Flawlessly Around the World

Retrieved on:

Monday, March 25, 2024

Aircraft, Altitude, Filter, Aviation, Record, Mach, Bombardier Global 7500, Atmosphere, Nuage, Safety, Atmosphere of Earth, Catreus, HEPA, Bombardier, FAI, Airline

The Global 7500 also set more than 20 new flight records(1) in the fall of 2023, including routes from Singapore to Anchorage, Alaska and Montreal to Geneva.

Key Points:

The Global 7500 also set more than 20 new flight records(1) in the fall of 2023, including routes from Singapore to Anchorage, Alaska and Montreal to Geneva.
The industry-defining Global 7500 jet is equally impressive when it comes to cabin design.
It also features the lowest cabin altitude of 2,900 feet when flying at 41,000 ft. – lower than any business jet today.
The Global 7500 record from Phoenix to Paris was set by charter firm Phenix Jet Cayman.

Kappa Delta Elizabeth Winston Lanier Award Presented to The ANCHOR Group for Improving Quality of Care for Young Patients With Pre-Arthritic Hip Conditions

Retrieved on:

Friday, February 2, 2024

This award recognizes research in musculoskeletal disease or injury with great potential to advance patient care.

Key Points:

This award recognizes research in musculoskeletal disease or injury with great potential to advance patient care.
"In the early 2000s, the orthopaedic community lacked an understanding of pre-arthritic hip disease diagnoses and treatments.
"Over the past 20 years, access to quality care for young patients with pre-arthritic hip disease has markedly improved" said Dr. Clohisy.
"We now have surgeons and health care teams who can deliver a comprehensive approach to manage the full spectrum of pre-arthritic hip disease.

“For the Industry, By the Industry”: CAIA Association Unveils Completely Redesigned Fundamentals of Alternative Investments Program

Retrieved on:

Wednesday, January 10, 2024

The Chartered Alternative Investment Analyst (CAIA) Association , the global professional body for the alternative investment industry, is today unveiling a completely redesigned and refreshed Fundamentals of Alternative Investments (FAI) program.

Key Points:

The Chartered Alternative Investment Analyst (CAIA) Association , the global professional body for the alternative investment industry, is today unveiling a completely redesigned and refreshed Fundamentals of Alternative Investments (FAI) program.
“The first generation of FAI played a critical role at a time when alternatives were just starting to go mainstream,” said Aaron Filbeck, CAIA, CFA, CFP®, CIPM, FDP, Managing Director, and Head of UniFi by CAIA™.
The new FAI is being launched this evening at Unveiling the Future: The Next $20 Trillion in Alternative Investments, Club 101, New York, NY at 5:30pm.
“Programs like this will help investment professionals deepen and broaden their understanding of and expertise in the evolving role of private investments in client portfolios.”
More information on UniFi by CAIA™ can be found here: https://caia.org/programs/unifi

American Heart Association Late-Breaking Science Presentation Reveals Majority of Adverse Cardiac Events Occur Among Patients Without Obstructive Coronary Artery Disease but Risks Are Detectable by Novel AI

Retrieved on:

Monday, November 13, 2023

PHILADELPHIA, Nov. 13, 2023 /PRNewswire/ -- New research, presented today at the American Heart Association's Late Breaking Science Sessions, has found that AI technology from Caristo Diagnostics can predict fatal and non-fatal cardiac events independently from routine clinical risk scores and coronary computed tomography angiography (CCTA) interpretation, and can significantly impact treatment for coronary artery disease (CAD) by transforming risk stratification and management of patients undergoing routine CCTA.

Key Points:

Clinical data from more than 40,000 patients were analyzed as part of the Oxford Risk Factors And Non-invasive imaging ( ORFAN ) study.
Among patients undergoing CCTA, the majority of fatal and non-fatal cardiac events occurred in those who did not have obstructive CAD at the time of imaging.
Specifically, there are twice as many heart attacks and cardiac deaths in the group without obstructive CAD versus those with obstructive CAD.
We look forward to introducing our technology across geographies to transform cardiac care and make heart attacks a preventable reality worldwide."

American Heart Association Late-Breaking Science Presentation Reveals Majority of Adverse Cardiac Events Occur Among Patients Without Obstructive Coronary Artery Disease but Risks Are Detectable by Novel AI

Retrieved on:

Monday, November 13, 2023

PHILADELPHIA, Nov. 13, 2023 /PRNewswire/ -- New research, presented today at the American Heart Association's Late Breaking Science Sessions, has found that AI technology from Caristo Diagnostics can predict fatal and non-fatal cardiac events independently from routine clinical risk scores and coronary computed tomography angiography (CCTA) interpretation, and can significantly impact treatment for coronary artery disease (CAD) by transforming risk stratification and management of patients undergoing routine CCTA.

Key Points:

Clinical data from more than 40,000 patients were analyzed as part of the Oxford Risk Factors And Non-invasive imaging ( ORFAN ) study.
Among patients undergoing CCTA, the majority of fatal and non-fatal cardiac events occurred in those who did not have obstructive CAD at the time of imaging.
Specifically, there are twice as many heart attacks and cardiac deaths in the group without obstructive CAD versus those with obstructive CAD.
We look forward to introducing our technology across geographies to transform cardiac care and make heart attacks a preventable reality worldwide."

Studies Investigate the Impact of Obesity on Outcomes after the Total Ankle Replacement (TAR) Procedure

Retrieved on:

Tuesday, October 17, 2023

Rosemont, Ill., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Total Ankle Replacement (TAR), also known as total ankle arthroplasty, is a surgical procedure that foot and ankle orthopaedic surgeons use to treat ankle arthritis.

Key Points:

Rosemont, Ill., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Total Ankle Replacement (TAR), also known as total ankle arthroplasty, is a surgical procedure that foot and ankle orthopaedic surgeons use to treat ankle arthritis.
Foot and ankle orthopaedic surgeons continue to investigate the factors that contribute to the success or failure of the procedure, including the impact of obesity.
The study titled “Total Ankle Arthroplasty: Does Obesity Matter?” reviewed data from 1,093 patients who underwent TAR at Duke between 2001 and 2020.
This is one of the largest single-institution studies to date examining the effect of obesity on outcomes after TAR.

HG Insights Launches Functional Area Intelligence, Significantly Enhancing Its Comprehensive One-Stop Technology Intelligence Solution

Retrieved on:

Thursday, August 3, 2023

Professional Services, Marketing, Data Management, Communications, Other Professional Services, Data Analytics, Technology, Universe, Business, FAI, Intelligence, Technology intelligence, HG, ROI, Retail, Sales

HG Insights®, the global leader in data-driven insights for technology vendors, announced today the introduction of HG Functional Area Intelligence.

Key Points:

HG Insights®, the global leader in data-driven insights for technology vendors, announced today the introduction of HG Functional Area Intelligence.
Functional Area Intelligence adds to the HG Platform’s multi-layered Technology Intelligence approach with location and department data added to existing insights on IT spend, technology installations, cloud usage, intent signals, and contract information.
HG Functional Area Intelligence was first made available last year through the HG Universe data subscription.
HG Insights’ Functional Area Intelligence includes:
Access to best-in-class quality data: HG’s insights combines Technology Intelligence and intent data with functional area intelligence to provide powerful insights down to the departmental level
Analyze technologies at the department level: Technology-specific predictions down to the department level to optimize sales motions